Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 3/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6863427 | 0.78 | CHRNB2 (0.52) | CHRNB2CHRNA4TSHRCHRNB4CHRNA3 | |
| SCHEMBL19798467 | 0.77 | CHRM2 (0.62) | CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL15141844 | 0.77 | CHRNB2 (0.36) | CHRNB2CHRNA4TSHRCHRNB4CHRNA3 | |
| SCHEMBL15142213 | 0.75 | CHRNB2 (0.35) | CHRNB2CHRNA4TSHRCHRNB4CHRNA3 | |
| SCHEMBL16728244 | 0.75 | CHRNB2 (0.38) | CHRNB2CHRNA4TSHRCHRNB4CHRNA3 | |
| SCHEMBL25242454 | 0.74 | CHRNB2 (0.50) | CHRNB2CHRNA4TSHRCHRNB4CHRNA3 | |
| SCHEMBL10196681 | 0.74 | CHRM1 (0.46) | CHRNB2CHRNA4TSHRGRM5CHRM2 | |
| SCHEMBL17559289 | 0.74 | CHRM1 (0.46) | CHRNB2CHRNA4TSHRGRM5CHRM2 | |
| SCHEMBL11734406 | 0.74 | CHRM1 (0.65) | CHRNB2CHRNA4TSHRGRM5CHRM2 | |
| SCHEMBL30998729 | 0.74 | CHRNB2 (0.50) | CHRNB2CHRNA4TSHRCHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119053596-A | Heterocyclic compounds as kinase inhibitors, compositions and methods of use | 捷思英达控股有限公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2023216237-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS, AND METHODS OF USE THEREOF | JS INNOMED HOLDINGS LTD. (KY) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023216237-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS, AND METHODS OF USE THEREOF | JS INNOMED HOLDINGS LTD. (KY) | 2023-11-16 | — | — | WO | disclosed |
| CN-114127080-B | Heterocyclic compounds as kinase inhibitors, compositions comprising the same, and methods of use thereof | 捷思英达医药技术（上海）有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20220220128-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2022-07-14 | — | — | US | disclosed |
| EP-3980425-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS InnoPharm (Shanghai) Ltd. (CN) | 2022-04-13 | — | — | EP | disclosed |
| CN-114127080-A | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compounds, and methods of use thereof | 捷思英达医药技术（上海）有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2020248972-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-12-17 | — | — | WO | disclosed |
| EP-2794607-B1 | DERIVATIVES OF AZA ADAMANTANE AND USES THEREOF | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2017-05-10 | — | — | EP | disclosed |
| EP-2221306-B1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | NISSAN CHEMICAL IND LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-20120310005-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | TOHOKU TECHNO ARCH CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-8273889-B2 | Method for producing 2-azaadamantane | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273889-B2 | Method for producing 2-azaadamantane | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273889-B2 | Method for producing 2-azaadamantane | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20100311977-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311977-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311977-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| CN-101861315-A | The manufacture method of 2-aza-adamantane class | NISSAN CHEMICAL IND LTD | 2010-10-13 | — | — | CN | disclosed |
| EP-2221306-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | Nissan Chemical Industries, Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
| EP-2221306-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | Nissan Chemical Industries, Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311977-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | CYP21A2, CYP51A1, CYP19A1 | CHRNB2 2211/4885CHRNA4 2274/4885TSHR 1043/4885 |
| US-20120310005-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | CYP21A2, CYP51A1, CYP19A1 | CHRNB2 2211/4885CHRNA4 2274/4885TSHR 1043/4885 |
| US-20220220128-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | RET, BRAF, ROR1 | CHRNB2 3758/4885CHRNA4 4505/4885TSHR 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.